Avadel Pharmaceuticals (AVDL) Free Cash Flow (2016 - 2022)
Historic Free Cash Flow for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2022 value amounting to -$15.4 million.
- Avadel Pharmaceuticals' Free Cash Flow rose 3172.49% to -$15.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$71.0 million, marking a year-over-year increase of 816.7%. This contributed to the annual value of -$46.9 million for FY2024, which is 6349.96% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Free Cash Flow of -$15.4 million as of Q4 2022, which was up 3172.49% from -$7.5 million recorded in Q3 2022.
- Avadel Pharmaceuticals' Free Cash Flow's 5-year high stood at -$1.4 million during Q2 2019, with a 5-year trough of -$34.0 million in Q1 2022.
- Moreover, its 5-year median value for Free Cash Flow was -$16.7 million (2018), whereas its average is -$15.9 million.
- Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 52128.44% in 2018, then surged by 9276.71% in 2019.
- Avadel Pharmaceuticals' Free Cash Flow (Quarter) stood at -$24.5 million in 2018, then surged by 66.37% to -$8.3 million in 2019, then plummeted by 132.52% to -$19.2 million in 2020, then fell by 17.28% to -$22.5 million in 2021, then surged by 31.72% to -$15.4 million in 2022.
- Its Free Cash Flow stands at -$15.4 million for Q4 2022, versus -$7.5 million for Q3 2022 and -$14.1 million for Q2 2022.